Skip to main content
SpringerLink
Log in

Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Spontaneous behaviours were assessed in freely moving rats after treatment with equimolar doses of drugs that share a basic amphetamine structure. The drugs used included a psychomotor stimulant [(+)-amphetamine (AMPH)], an hallucinogen [para-methoxyamphetamine (PMA)] and the entactogens 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxy-N-ethylamphetamine (MDE). A detailed analysis of the frequency and duration of 30 different behaviours and the temporal organization of the behaviours was conducted in addition to measuring motor activity with an automated device. Levels of the biogenic amines and their acid metabolites in discrete brain regions and brain drug levels were also obtained. The automated motor activity measures discriminated among entactogens, the stimulant and the hallucinogen, but failed to distinguish between the hallucinogen and vehicle. Principal components analysis and cluster analysis of the frequencies and durations of the behaviours did not improve the classification of the drugs over the automated motor activity measures. Only the cluster analysis of the transitions between individual behaviours succeeded in differentiating the drug classes from each other and from vehicle treatment. All the behavioural measures classified one entactogen (MDE) as an hallucinogen. Cortical 5-hydroxytryptamine (5-HT) measures grouped MDE with the other entactogens but did not distinguish AMPH from vehicle. However, striatal dopamine measures differentiated AMPH from vehicle treatment. Variations in the durations of behavioural effects across drugs were associated with large differences in drug levels 3 h after injection. Although the neurochemical data provided a classification system that most closely parallels human subjective effects of these drugs, both the neurochemical and the behavioural measures supported the existence of an entactogen class distinct from a psychomotor stimulant and an hallucinogen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Baker GB, Coutts RT, Rao TS (1987) Neuropharmacological and neurochemical properties ofN-(cyanoethyl)-β-phenylethylamine, a prodrug ofβ-phenylethylamine. Br J Pharmacol 92:243–256

    Google Scholar 

  • Ellison GD (1991) Animal models of hallucinations. In: Boulton AA, Baker GB, Martin-Iverson MT (eds) Neuromethods vol. 18: Animal models in psychiatry. Humana Press, Totowa, N.J., pp 151–187

    Google Scholar 

  • Evenden JL, Robbins TW (1983) Increased response switching, perseveration and perseverative switching followingd-amphetamine in the rat. Psychopharmacology 80:67–73

    Google Scholar 

  • Gibb JW, Stone D, Johnson M, Hanson GR (1990) Neurochemical effects of MDMA. In: Peroutka SJ (ed) Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA. Kluwer Academic Publishers, Boston, pp 133–150

    Google Scholar 

  • Glennon RA (1990) Serotonin receptors: clinical implications. Neurosci Biobehav Rev 14:35–47

    Google Scholar 

  • Glennon RA (1992) Animal models for assessing hallucinogenic agents. In: Boulton AA, Baker GB, Wu PH (eds) Neuromethods vol. 24: models of drug addiction. Humana Press, Totowa, N. J., pp 345–381

    Google Scholar 

  • Glennon RA, Young R (1984a) MDA: a psychoactive agent with dual stimulus effects. Life Sci 34:379–383

    Google Scholar 

  • Glennon RA, Young R (1984b) Further investigation of the discriminative properties of MDA. Pharmacol Biochem Behav 20:501–505

    Google Scholar 

  • Green AL, EI Hait MAS (1980)p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo. J Pharm Pharmacol 32:262–266

    Google Scholar 

  • Haberman SJ (1973) The analysis of residuals on cross-classified tables. Biometrics 29:205–220

    Google Scholar 

  • Hegadoren KM, Baker GB, Coutts RT (1993) The simultaneous separation and quantitation of the enantiomers of MDMA and MDA using gas chromatography with nitrogen-phosphorus detection. Res Commun Subst Abuse 14:67–80

    Google Scholar 

  • Hermle L, Spitzer M, Borchardt D, Kovar KA, Gouzoulis E (1993) Psychological effects of MDE in normal subjects — are entactogens a new class of psychoactive agents? Neuropsychopharmacology 8:171–176

    Google Scholar 

  • Hitzeman RJ, Loh HH, Domino EF (1971) Effects ofpara-methoxyamphetamine on catecholamine metabolism in the mouse brain. Life Sci 10:1087–1095

    Google Scholar 

  • Jacobs BL (1984) Postsynaptic serotonergic action of hallucinogens. In: Jacobs BL (ed) Hallucinogens: neurochemical, behavioral and clinical perspectives. Raven Press, New York, pp 183–202

    Google Scholar 

  • Jacobs BL, Trulson MC, Stern WC (1976) An animal behavior model for studying the actions of LSD and related hallucinogens. Science 194:741–743

    Google Scholar 

  • Johnson M, Hanson GR, Gibb JW (1987) Effects ofN-ethyl-3,4-methylenedioxyamphetamine (MDE) on central serotonergic and dopaminergic systems of the rat. Biochem Pharmacol 36:4085–4093

    Google Scholar 

  • Johnson M, Hanson GR, Gibb JW (1989) Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog. Eur J Pharmacol 165:315–318

    Google Scholar 

  • Martin WR, Vaupel DB, Nozaki M, Bright LD (1978) The identification of LSD-like hallucinogens using the chronic spinal dog. Drug Alchol Depend 3:113–123

    Google Scholar 

  • Martin-Iverson MT (1991) An animal model of stimulant psychoses. In: Boulton AA, Baker GB, Martin-Iverson MT (eds) Neuromethods vol. 18: Animal models in psychiatry. Humana Press, Totowa, N. J., pp 103–149

    Google Scholar 

  • Matthews RT, Champney TH, Frye GD (1989) Effects of (±) 3,4-methylenedioxymethamphetamine (MDMA) on brain dopaminergic activity in rats. Pharmacol Biochem Behav 33:741–747

    Google Scholar 

  • McKenna DJ, Guan X-M, Shulgin AT (1991) 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of3H-dopamine and3H-5-hydroxytryptamine. Pharmacol Biochem Behav 38:505–512

    Google Scholar 

  • Menon KM, Tseng L, Loh HH (1976) Pharmacological evidence for the central effects of monomethoxyamphetamines. J Pharmacol Exp Ther 197:272–279

    Google Scholar 

  • Mokler DJ, Robinson SE, Rosecrans JA (1987) (±)-3,4-Methylenedioxymethamphetamine (MDMA) produces long term reductions in brain 5-hydroxytryptamine in rats. Eur J Pharmacol 138:265–268

    Google Scholar 

  • Moore KE (1978) Amphetamines: biochemical and behavioral actions in animals. In: Iversen LL, Iversen SD, Synder SH (eds) Handbook of psychopharmacology vol. 11. Plenum Press, New York, pp 41–98

    Google Scholar 

  • Nichols DE (1986) Differences between the mechanisms of action of MDMA, MDBD and the classical hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18:305–313

    Google Scholar 

  • Nichols DE, Hoffman AJ, Oberlender R, Jacob P, Shulgin AT (1986) Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J Med Chem 29:2009–2015

    Google Scholar 

  • Nichols DE, Oberlender R (1990) Structure-activity relationships of MDMA and related compounds: a new class of psychoactive agents? In: Peroutka SJ (ed) Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA. Kluwer, Boston, pp 53–62

    Google Scholar 

  • Norton S (1968) On the discontinuous nature of behavior. J Theoret Biol 21:229–243

    Google Scholar 

  • Norton S (1973) Amphetamine as a model for hyperactivity in the rat. Physiol Behav 11:181–186

    Google Scholar 

  • Robbins TW, Mittleman G, O'Brien J, Winn P (1990) The neuropsychological significance of stereotypy induced by stimulant drugs. In: Cooper SJ (ed) Neurobiology of stereotyped behavior. Oxford University Press, London, pp 25–63

    Google Scholar 

  • Schmidt CJ, Taylor VL (1990) Neurochemical effects of methylenedioxymethamphetamine in the rat: acute versus long term changes. In: Peroutika SJ (ed) Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA. Kluwer, Boston, pp 53–62

    Google Scholar 

  • Segal DS, Schuckit MA (1983) Animal models of stimulant-induced psychosis. In: Creese I (ed) Stimulants: neurochemical, behavioural and clinical perspectives. Raven Press, New York, pp 131–167

    Google Scholar 

  • Shulgin AT (1978) Psychomimetic drugs: structure-activity relationships. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology, vol. 1. Plenum Press, New York, pp 243–333

    Google Scholar 

  • Shulgin AT, Nichols DE (1978) Characterization of three new psychotomimetics. In: Stillman RC, Willette RE (eds) The psychopharmacology of hallucinogens. Pergamon Press, New york, pp 74–83

    Google Scholar 

  • Shulgin AT, Sargent T, Naranjo C (1969) Structure-activity relationships of one-ring psychomimetics. Nature 221:537–541

    Google Scholar 

  • Spanos LJ, Yamamoto BK (1989) Acute and subchronic effects of methylenedioxymethamphetamine [(±) MDMA] on locomotion and the serotonin syndrome behaviour in the rat. Pharmacol Biochem Behav 32:835–840

    Google Scholar 

  • Thiessen PN, Cook DA (1973) The properties of 3,4-methylene-dioxyamphetamine (MDA). A review of the literature. Clin Toxicol 6:45–52

    Google Scholar 

  • Tseng L, Menon MK, Loh HH (1976) Comparative actions of monomethoxyamphetamines on the release and uptake of biogenic amines in brain tissue. J Pharmacol Exp Ther 197:263–271

    Google Scholar 

  • Winter JC (1984) The stimulus properties ofpara-methoxyamphetamine: a nonessential serotonergic component. Pharmacol Biochem Behav 20:201–203

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurochemical Research Unit, Department of Psychiatry, University of Alberta, T6G 2B7, Edmonton, Alberta, Canada

    K. M. Hegadoren, M. T. Martin-Iverson & G. B. Baker

Authors
  1. K. M. Hegadoren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. T. Martin-Iverson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. B. Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hegadoren, K.M., Martin-Iverson, M.T. & Baker, G.B. Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine. Psychopharmacology 118, 295–304 (1995). https://doi.org/10.1007/BF02245958

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02245958

Key words

Search

Navigation